Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25


19310 items
5:24 PM, Jun 05, 2018  |  BioCentury | Product Development

Second (Ex)act

Armed with Phase II data for its second DNA methylation test, Exact Sciences Corp. expects a repeat performance of the rapid launch trajectory its Cologuard colorectal cancer screening assay has enjoyed. Cologuard beat expectations for...
10:25 AM, Jun 02, 2018  |  BioCentury | Politics, Policy & Law

Getting flatter

Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, brought the center’s entire staff of about 5,000 people together in the agency’s Great Room on June 1 for a town hall meeting to...
10:50 PM, Jun 01, 2018  |  BioCentury | Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
10:29 PM, Jun 01, 2018  |  BioCentury | Strategy

Partnering on a mission

With a $260 million war chest and a banner roster of execs, advisors and deals, Brii Biosciences is pushing an agenda to bring infectious diseases to the forefront of innovation in China. Its top priority...
6:30 PM, Jun 01, 2018  |  BioCentury | Product Development

ASCO: Pushing precision’s evolution

As the list of targeted therapies gaining approval grows, encompassing an increasingly broad spectrum of cancers, this year’s ASCO meeting aims to educate clinicians about how to determine which drugs are best in class for...
3:11 PM, Jun 01, 2018  |  BioCentury | Emerging Company Profile

Scratching the surface

Oppilotech Ltd. is using computational modeling to develop first-in-class compounds that can permeate the lipopolysaccharide layer of the outer cell membrane of Gram-negative bacteria to potentiate existing antibiotics. Marketed polymyxins are used to disrupt the lipopolysaccharide...
3:05 PM, Jun 01, 2018  |  BioCentury | Finance

Bacterial brain

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B. The round closed on May 31 with...
2:29 PM, Jun 01, 2018  |  BioCentury | Finance

CalPERS goes direct

The strong performance of direct life science investments made by some sovereign wealth or pension funds could be part of the rationale for CalPERS’s plan to launch its own direct investment fund that could funnel...
1:08 PM, Jun 01, 2018  |  BioCentury | Finance

Distribution to innovation

Chinese drug distributor Sinopharm plans to close additional renminbi and U.S. dollar funds this year to back innovative biotechs. According to Sinopharm Capital’s Liang Deng, China National Pharmaceutical Group Corp. (Sinopharm) is the largest pharmaceutical distributor...
2:10 PM, May 25, 2018  |  BioCentury | Finance

Buyback Band-Aid

A $3 billion expansion of its share buyback program won’t help Celgene Corp. (NASDAQ:CELG) address the long-term pipeline problems that concern a trio of buysiders, who would rather see the big biotech put the spending...